Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocular Therapeutix Inc OCUL

Healthcare
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular... see more

Recent & Breaking News (NDAQ:OCUL)

How These Biotech Stocks are Faring? -- Ocular Therapeutix, Idera Pharma, Conatus Pharma, and Infinity Pharma

PR Newswire November 4, 2016

Ocular Therapeutix™ to Hold Third Quarter 2016 Financial Results Conference Call on Wednesday, November 9, 2016

Business Wire November 2, 2016

Ocular Therapeutix™ Strengthens Management Team with the Appointment of Andy Hurley as Chief Commercial Officer

Business Wire October 20, 2016

Deal With Regeneron Means Validation For Ocular Therapeutix

Benzinga.com  October 13, 2016

Mid-Afternoon Market Update: Lindsay Gains Following Q4 Results; Fluidigm Shares Drop

Benzinga.com  October 13, 2016

10 Biggest Mid-Day Gainers For Thursday

Benzinga.com  October 13, 2016

Mid-Day Market Update: Ocular Therapeutix Surges Following Collaboration Deal With Regeneron; Flex Pharma Shares Slide

Benzinga.com  October 13, 2016

Ocular Therapeutix™ Outlines Development Strategy for Its Sustained Release Intravitreal Depots to Address Serious Retinal Diseases

Business Wire October 13, 2016

Ocular Therapeutix™ and Regeneron Enter Into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases

Business Wire October 13, 2016

Ocular Therapeutix™ Begins Enrollment in First Phase 3 Clinical Trial with OTX-TP (Sustained Release Travoprost) for the Treatment of Glaucoma and Ocular Hypertension

Business Wire October 4, 2016

Ocular Therapeutix™ to Participate in the Morgan Stanley Global Healthcare Conference

Business Wire August 31, 2016

20 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  August 16, 2016

15 Biggest Mid-Day Gainers For Monday

Benzinga.com  August 15, 2016

12 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  August 15, 2016

18 Biggest Mid-Day Gainers For Friday

Benzinga.com  August 12, 2016

18 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  August 12, 2016

Ocular Therapeutix™ Reports Second Quarter 2016 Financial Results and Provides Corporate Update

Business Wire August 9, 2016

11 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  August 8, 2016

Ocular Therapeutix™ Announces Presentation at the Ophthalmology Innovation Summit (OIS) at the American Society of Retina Specialists (ASRS)

Business Wire August 5, 2016

Mid-Morning Market Update: Markets Edge Lower; Viacom Tops Q3 Expectations

Benzinga.com  August 4, 2016